Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Short term Debt (2022 - 2026)

Axsome Therapeutics' Short term Debt history spans 5 years, with the latest figure at $11.2 million for Q1 2026.

  • On a quarterly basis, Short term Debt rose 29.62% to $11.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.2 million, a 29.62% increase, with the full-year FY2025 number at $10.0 million, changed N/A from a year prior.
  • Short term Debt hit $11.2 million in Q1 2026 for Axsome Therapeutics, up from $10.0 million in the prior quarter.
  • Over the last five years, Short term Debt for AXSM hit a ceiling of $70.0 million in Q2 2025 and a floor of $5.9 million in Q4 2022.
  • Historically, Short term Debt has averaged $11.7 million across 5 years, with a median of $7.0 million in 2022.
  • Biggest five-year swings in Short term Debt: dropped 4.69% in 2023 and later soared 894.32% in 2025.
  • Tracing AXSM's Short term Debt over 5 years: stood at $5.9 million in 2022, then rose by 8.59% to $6.4 million in 2023, then increased by 26.91% to $8.1 million in 2024, then grew by 23.13% to $10.0 million in 2025, then grew by 11.37% to $11.2 million in 2026.
  • Business Quant data shows Short term Debt for AXSM at $11.2 million in Q1 2026, $10.0 million in Q4 2025, and $9.7 million in Q3 2025.